Jacobs Levy Equity Management
DNTH icon

Jacobs Levy Equity Management’s Dianthus Therapeutics DNTH Stock Holding History

Jacobs Levy Equity Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,232
Closed -$144K – 994
2021
Q3 		$144K Sell
1,232
-8,299
-87% -$967K ﹤0.01% 1006
2021
Q2 		$1.49M Buy
9,531
+128
+1% +$23.5K 0.01% 657
2021
Q1 		$1.78M Sell
9,403
-2,809
-23% -$473K 0.01% 621
2020
Q4 		$1.53M Buy
12,212
+9,934
+436% +$1.13M 0.01% 630
2020
Q3 		$248K Sell
2,278
-180
-7% -$21.3K ﹤0.01% 921
2020
Q2 		$295K Buy
+2,458
New +$346K ﹤0.01% 889

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management's DNTH Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Dianthus Therapeutics (DNTH) in Q4 2021, closing a stake of 1,232 shares — an estimated $144K sold.

Jacobs Levy Equity Management first reported a position in DNTH in Q2 2020 and held it in 6 quarters. The position peaked at $1.78M in Q1 2021. 94 funds tracked by Wall St. Rank hold DNTH as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Dianthus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 1,232 Dianthus Therapeutics shares in Q4 2021, an estimated $144K.
  • Jacobs Levy Equity Management first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 6 quarters.
  • Jacobs Levy Equity Management's Dianthus Therapeutics position peaked at $1.78M in Q1 2021.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.